SorCS3 Antibody [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 350

SorCS3 Antibody [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human SorCS3
  Glu34-Ser1125
  Accession # Q9UPU3
• Specificity: Detects human SorCS3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 40% cross-reactivity with recombinant mouse SorCS3 is observed and 5% cross-reactivity with recombinant human SorCS1 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SorCS3 Antibody [Alexa Fluor® 350]

• 6330404A12Rik
• KIAA1059SORCS
• SorCS3
• sortilin-related VPS10 domain containing receptor 3
• VPS10 domain receptor protein SORCS 3 (SORCS3)
• VPS10 domain-containing receptor SorCS3

Background

SorCS3 (sortilin-related YPS10 domain containing receptor 3) is a type I transmembrane receptor that belongs to the mammalian Vps10p (vacuolar protein-sorting 10 protein) family of sorting receptors. This family includes sortilin, SorLA, and three SorCS proteins (1, 2). It is synthesized as a 1222 amino acid (aa) preproform with a 33 aa signal sequence and a 100 aa propeptide. After proteolytic processing at a furin-type consensus sequence, mature SorCS3 is generated that is 100‑110 kDa in size and 1089 aa in length. It contains a 992 aa extracellular/lumenal domain (ECD), a 21 aa transmembrane segment and a 76 aa cytoplasmic domain. Human SorCS3 ECD shares 92%, 93%, 94% and 91% aa identity with mouse, rat, bovine and canine SorCS3 ECD, respectively. It also shares 70% and 46% aa identity with human SorCS1 and SorCS2 ECD, respectively. The ECD contains an imperfect leucine-rich repeat (LRR) and a Vps10p domain that binds both pro- and mature NGF (2, 3). The ECD may be shed constitutively, or up‑regulated when induced by phorbol esters (4). The metalloproteinase TACE/ADAM17 is known to cleave SorCS3 near the membrane (4). The shed ECD is able to bind PDGF-BB and the NGF propeptide (4, 5). The function of the SorCS3 propeptide is unknown. It does not block activity or influence protein processing in a manner analogous to the sortilin propeptide (3, 5). SorCS3 is predominantly expressed on the plasma membrane where it can be slowly internalized (3). Despite the presence of a sorting domain, there is no evidence for SorCS3-mediated intracellular trafficking activity (3). It is expressed in mouse embryonic and adult central nervous system in areas distinct from that of SorCS1 and SorCS2 (1). Neuronal activity up‑regulates SorCS3 expression in the mouse hippocampus (1).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.